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Background: The aim of this bachelor thesis was to evaluate the efficacy of neoadjuvant
chemotherapy in patients with breast cancer, its statistical evaluation and the prognostic
value of pathologic complete response (pCR).
Methods: The data set of 77 patients after administration of neoadjuvant chemotherapy was
compiled and evaluated. Information was obtained by exploring the medical records.
Results: All patients underwent the surgery after administration of neoadjuvant
chemotherapy. 26, 2 % of the patients with breast cancer after administration of neoadjuvant
chemotherapy achieved pCR. Higher pCR rate (29 %) was observed in elderly patients over
the age of 40 years. Significantly higher frequency of pCR (42,4 %) was determined
in patients with earlier clinical stage of the disease. Significantly higher pCR rate (50 %) was
found in patients treated by taxane with the addition of carboplatin. Contribution of pCR
on progression-free survival could not be demonstrated because of the low number
of patients with determined disease progression. Achieved pCR in patients correlated
with a higher 3 -year overall survival, the difference was not considered as statistically
significant due to the small number of patients.
Conclusion: The benefit of the administration of neoadjuvant chemotherapy on the rate
of performed surgeries was confirmed. Determined achieved pCR was consistent
with published data. Different pCR rate was established according to the treatment regimens
administered, age group and clinical stage of the disease. Contribution of pCR
on progression-free survival and overall survival should be confirmed by additional
monitoring with higher patients cohort.
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